CD367/CLEC4A Protein, Human (HEK293, His)

The CD367/CLEC4A protein is a C-type lectin receptor that prefers to bind mannose and fucose and interacts weakly with GlcNAc in a Ca(2+)-dependent manner. It is critical for immune regulation, undergoing clathrin-dependent endocytosis upon antigen triggering, leading to antigen presentation and cross-priming of CD8+ T cells. CD367/CLEC4A Protein, Human (HEK293, His) is the recombinant human-derived CD367/CLEC4A protein, expressed by HEK293 , with N-His labeled tag. The total length of CD367/CLEC4A Protein, Human (HEK293, His) is 168 a.a., with molecular weight of 24-26 kDa.

CD367/CLEC4A protein functions as a C-type lectin receptor with a preference for binding carbohydrates mannose and fucose, and a weaker interaction with N-acetylglucosamine (GlcNAc) in a Ca(2+)-dependent manner. This receptor plays a crucial role in regulating immune reactivity and, upon antigen triggering, undergoes internalization through clathrin-dependent endocytosis. Consequently, it delivers its antigenic cargo into the antigen presentation pathway, leading to the cross-priming of CD8(+) T cells. Notably, this cross-presentation and cross-priming are augmented by TLR7 and TLR8 agonists, resulting in increased expansion of CD8(+) T cells and heightened production of IFNG and TNF, while reducing levels of IL4, IL5, and IL13. In plasmacytoid dendritic cells, CD367/CLEC4A inhibits TLR9-mediated IFNA and TNF production. Furthermore, it may be involved in the inhibition of B-cell-receptor-mediated calcium mobilization and protein tyrosine phosphorylation via its ITIM motif (immunoreceptor tyrosine-based inhibitory motifs). In the context of microbial infection, CD367/CLEC4A is implicated in the interaction between HIV-1 virus and dendritic cells, enhancing HIV-1 binding and virus infection through an ITIM motif-associated signal transduction pathway involving phosphatases PTPN6 and PTPN11, SYK, Src kinases, and MAP kinases.

Measured by its ability of the immobilized protein to support the adhesion of Jurkat human acute T cell leukemia cells. The ED₅₀ for this effect is 1.260 μg/mL, corresponding to a specific activity is 793.651 units/mg

Human

HEK293

N-6*His

Q9UMR7-1 (Q70-L237)

50856  [NCBI]

QKYSQLLEKKTTKELVHTTLECVKKNMPVEETAWSCCPKNWKSFSSNCYFISTESASWQDSEKDCARMEAHLLVINTQEEQDFIFQNLQEESAYFVGLSDPEGQRHWQWVDQTPYNESSTFWHPREPSDPNERCVVLNFRKSPKRWGWNDVNCLGPQRSVCEMMKIHL

Approximately 24-26 kDa due to the glycosylation.

Greater than 95% as determined by reducing SDS-PAGE

Lyophilized powder.

Lyophilized from a 0.2 μm filtered solution of PBS, pH 7.4.

<1 EU/μg, determined by LAL method.

It is not recommended to reconstitute to a concentration less than 100 μg/mL in ddH₂O. For long term storage it is recommended to add a carrier protein (0.1% BSA, 5% HSA, 10% FBS or 5% Trehalose).

Stored at -20°C for 2 years. After reconstitution, it is stable at 4°C for 1 week or -20°C for longer (with carrier protein). It is recommended to freeze aliquots at -20°C or -80°C for extended storage.

Room temperature in continental US; may vary elsewhere.